fda bans compounded semaglutide "semaglutide" is not FDA-approved Compounded Semaglutide & Tirzepatide 2025:

To date, they represent the only G protein-coupled receptor (GPCR) ligands approved as glucose-lowering agents (2)

The higher dosage is designed to target appetite regulation and promote significant, sustained weight loss

Much of this interest is driven by early research coverage and online discussion, which can make it difficult to separate established medical information from speculation

In patients wanting aesthetic treatment while weight loss is ongoing, we believe that informed consent is a key nonclinical consideration

The defense has successfully delayed the lawsuit by arguing that the judge should first determine whether the warning label precludes certain claims, such as gastroparesis